Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several high-level statements align with the BETHKIS label (CF with P. aeruginosa; oral inhalation-only; key aminoglycoside safety issues). However, multiple claims are either overly general, not supported with the provided label excerpts (e.g., route-dependent comparisons, “tablet” comparisons, “certain chronic lung infections”), or inaccurate relative to the specific BETHKIS indication/exclusions (pediatric age <6, FEV1 range, Burkholderia cepacia).
Category Scores
Accurate Statements
Inhaled tobramycin is commonly used in specific patient populations such as cystic fibrosis.
BETHKIS is indicated for cystic fibrosis patients with Pseudomonas aeruginosa (INDICATIONS AND USAGE).
Tobramycin has major risks of nephrotoxicity (kidney irritation).
Nephrotoxicity caution/monitoring is included in WARNINGS AND PRECAUTIONS (5.2).
Tobramycin has major risks of ototoxicity (hearing/balance effects).
Ototoxicity caution/monitoring is included in WARNINGS AND PRECAUTIONS (5.1).
Whether nephrotoxicity and ototoxicity risks apply depends on the formulation and how much drug reaches the bloodstream.
Label states systemic absorption following inhaled administration is expected to be minimal (12.3) and provides route-based cautions/monitoring. (While exact wording about formulation/bloodstream is not stated, the minimal systemic absorption concept supports reduced systemic exposure expectation.)
Unsupported Statements
Tobramycin is not commonly marketed as an oral tablet in the way many antibiotics are.
Not addressed in the provided BETHKIS label excerpts.
Tobramycin is widely used in inhaled formulations.
Not addressed in the provided BETHKIS label excerpts.
Inhaled tobramycin is used for lung infections in certain patients.
The label excerpt provided specifies cystic fibrosis patients with Pseudomonas aeruginosa; it does not broadly describe “lung infections” in general terms.
Tobramycin is used in topical, eye, ear, or injected forms depending on the product.
The provided label excerpt is specific to BETHKIS (oral inhalation only) and does not support claims about other tobramycin formulations/routes.
Inhaled tobramycin is used for certain chronic lung infections.
Not supported by the provided BETHKIS label excerpts.
Local use of tobramycin is used for eye or ear infections depending on the specific product.
Not supported by the provided BETHKIS label excerpts (BETHKIS is not for topical/eye/ear administration).
Systemic use of tobramycin is injection for severe bacterial infections when clinicians choose an aminoglycoside.
Not supported by the provided BETHKIS label excerpts.
Risk profiles differ by route (tablet vs inhaled vs injected).
The label excerpt discusses aminoglycosides and includes cautions for inhaled BETHKIS, and also notes ototoxicity/nephrotoxicity are reported with parenteral aminoglycosides. However, it does not support a general “tablet vs inhaled vs injected” comparative risk statement in the way made here.
Contradictions
Low
AI Statement
Inhaled tobramycin is used for lung infections in certain patients.
Label Reference
INDICATIONS AND USAGE: BETHKIS is indicated specifically for cystic fibrosis patients with Pseudomonas aeruginosa; the label excerpt provided does not support a broader “lung infections” framing.
Low
AI Statement
Tobramycin is used in topical, eye, ear, or injected forms depending on the product.
Label Reference
DOSAGE AND ADMINISTRATION: BETHKIS is for oral inhalation only; not subcutaneous, intravenous, or intrathecal; and label is specific to BETHKIS administration instructions.
Important Omissions
BETHKIS-specific dosing details (one single-use ampule 300 mg/4 mL twice daily by oral inhalation; repeated cycles 28 days on/28 days off; spacing guidance; missed-dose instructions).
Importance:
Moderate
BETHKIS-specific pediatric limitation and patient eligibility exclusions (not studied/safety/efficacy not demonstrated in patients under 6 years; FEV1 <40% or >80%; Burkholderia cepacia colonization).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some correct safety concepts (ototoxicity/nephrotoxicity) but also makes multiple unsupported/generalized route and indication statements and omits key BETHKIS-specific eligibility/exclusion criteria and dosing instructions, which could lead to misapplication of the label to inappropriate patients.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple generalized statements about tobramycin formulations/routes and lung infection use are not supported by the provided BETHKIS label excerpts, and key BETHKIS dosing and patient eligibility details are omitted.
Suggested Improvement
Restrict claims to BETHKIS-specific labeling: CF patients with P. aeruginosa; oral inhalation only; include the exact 300 mg/4 mL twice-daily dosing in 28 days on/28 days off cycles; and note label limitations/exclusions (age <6, FEV1 range, Burkholderia cepacia). Remove or qualify statements about other tobramycin routes (topical/eye/ear/injection) not covered by the BETHKIS label excerpts.